Meet an IMDA Member - PneumaCare
PneumaCare is a Cambridge, U.K.-based
company, developing and marketing revolutionary non-contact,
non-invasive respiratory imaging systems. Founded in 2009, the
company initially focused on the need for better lung function
assessment in children. Since that time, PneumaCare has expanded
this focus to include adults in the lung function, ICU and
thoracic surgery segments.
Its flagship product, Thora3DIâ„¢, uses the PneumaViewâ„¢ system
operating platform and the PneumaViewâ„¢3D analysis software to
provide clinicians with te first, real-time, non-contact,
non-invasive bedside imaging of a patientâ€™s tidal breathing.
This output allows the clinician to view the regional chest wall
movement contributions and analyze these for unexpected
asymmetries due to respiratory-related issues.
Thanks to its mobile design,
Thora3DIâ„¢ can gather recordable data on seated patients in a
clinic or other outpatient setting, or at the patientâ€™s bedside
in the hospital.
PneumaCare has embarked on a clinical trial in California on
patients with chronic obstructive pulmonary disease. Learn more
about PneumaCare â€“ including publications, FAQs, testimonials
and more â€“ at
fantastic colors. Advise your manufacturer partners
to spruce up their devices with some color (e.g., Immortal Blue)
or special effects (e.g., pearlescent, glow-in-the-dark, even
Company, a supplier of thermoplastic compounds, has created
the Hueforia offering to help device companies evoke a response
and reinforce the brand.
value of mergers and acquisitions in the medical
device field was higher in the second quarter than in any other
healthcare subsector, according to
research from PwC, reports MD+DI. The value of medical
device deals in the quarter was $37.billion, driven in large
part by BDâ€™s $25.7 billion purchase of C.R. Bard as well as
Cardinalâ€™s $6.1 billion acquisition of Medtronic's Patient Care,
Deep Vein Thrombosis and Nutritional Insufficiency business.
devices and cybersecurity. Government-sponsored
hackers were seen as the biggest threat to cybersecurity among
executives in charge of technology, information, and security at
drug and medical device makers, according to the
2017 Cyber Healthcare & Life Sciences Survey from KPMG LLP.
The data that hackers are seeking are mostly tied to financial
information (69 percent) followed by patents and clinical
research (63 percent), the survey of 100 U.S. tech, data,
security executives from life sciences companies found.
"Some nations desperately want intellectual
property to support local life sciences organizations without
incurring R&D costs and challenges," said David Remick, a KPMG
partner who works with life sciences companies.
"Drug and medical device makers have
significant volumes of valuable financial and clinical
information," said Life Sciences Advisory Leader Alison Little.
"Recent cyber events targeting the life sciences industry
demonstrate that market capitalization can be immediately eroded
depending on the nature of the cyberattack and extent of
"The life science industry is increasingly engaging
patients directly through web portals and apps to help them
better manage their conditions, but this opens the door to new
risks," said Michael Ebert, a KPMG partner who leads cyber for
the Healthcare & Life Sciences Practice